NSCLC HER2 Alterations Therapies

CME

Medical Minute 2: Current and Emerging Therapies for Advanced NSCLC With HER2 Mutations and HER2 Overexpression

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: October 18, 2024

Expiration: April 17, 2025

Misako Nagasaka
Misako Nagasaka, MD, PhD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following findings was reported with zongertinib, a novel TKI, in patients with previously treated advanced, HER2-mutated NSCLC who enrolled in the Beamion Lung-1 phase I trial?